Israel Biotech Fund is a Rehovot-based venture capital firm founded in 2014 by Dr. See sector focus and contact routes.
Israel Biotech Fund is a Rehovot-based venture capital firm founded in 2014 by Dr. David Sidransky and Yuval Cabilly to maximize the success of therapeutic assets from Israeli biotech companies. The firm invests exclusively in Israeli and Israeli-related biotechnology and pharmaceutical companies developing drugs, with a focus on clinical-stage assets in oncology and immuno-oncology. Its initial $100 million fund and a subsequent $112 million fund are backed by limited partners including Biogen and Harel Insurance. While specific check sizes and lead/follow behavior are not publicly detailed, the firm’s first investment was a $45 million Series C in Ukko (Vidac) in January 2026, suggesting substantial follow-on capacity. Notable portfolio companies include Ayala Pharmaceuticals, Biond Biologics, Biosight, and Ukko. A distinctive feature is its team of 25 Venture Advisors, including industry veterans like Sol Barer and former Pfizer CEO Jeff Kindler, who provide hands-on strategic guidance to portfolio firms.
StartupFundraising tracks this firm record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to comparable investors.
Investors like Israel Biotech Fund · Full investor directory · Investor access · Company funding database